{"content":"<li class=\"n-box-item date-title\" data-end=\"1490673599\" data-start=\"1490587200\" data-txt=\"Sunday, December 22, 2019\">Monday, March 27, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3253705\" data-ts=\"1490650672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253705-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/PSIX' title='Power Solutions International, Inc.'>OTCPK:PSIX</a> <font color='green'>+47.0%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+8.3%</font>. <a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a> <font color='green'>+6.3%</font>. <a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='green'>+5.2%</font>. <a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a> <font color='green'>+4.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a> <font color='red'>-4.0%</font>. <a href='https://seekingalpha.com/symbol/BTE' title='Baytex Energy Corp.'>BTE</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a> <font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/DOOR' title='Masonite International Corporation'>DOOR</a> <font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/TVIX' title='VelocityShares Daily 2x VIX Short-Term ETN'>TVIX</a> <font color='red'>-2.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253705\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$PSIX $VSTM $OCN - After Hours Gainers / Losers https://seekingalpha.com/news/3253705-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3253705-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253703\" data-ts=\"1490649874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INAP\" target=\"_blank\">INAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253703-internap-files-resale-of-27_2m-common-stock-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Internap files resale of 27.2M common stock shares</a></h4><ul><li><a href=\"https://seekingalpha.com/filing/3475938\" target=\"_blank\">To be sold</a>&nbsp;by selling stockholders from time to time through a proposed approximate $94.7M maximum aggregate offering at a proposed maximum price of $3.48 per share.</li><li>Internap (NASDAQ:<a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a>) $3.65,&nbsp;<font color='red'>-3.7%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3253703\" data-linked=\"Internap files resale of 27.2M common stock shares\" data-tweet=\"$INAP - Internap files resale of 27.2M common stock shares https://seekingalpha.com/news/3253703-internap-files-resale-of-27_2m-common-stock-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3253703-internap-files-resale-of-27_2m-common-stock-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253701\" data-ts=\"1490649058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRI\" target=\"_blank\">DRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253701-darden-restaurants-buys-cheddars-scratch-kitchen-for-780m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Darden Restaurants buys Cheddar&#39;s Scratch Kitchen for $780M</a></h4><ul><li>Darden Restaurants (NYSE:<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a>) <a href=\"https://seekingalpha.com/pr/16782066-darden-restaurants-agrees-acquire-cheddars-scratch-kitchen-780-million-adds-casual-dining\" target=\"_blank\">agrees to acquire</a> Cheddar's Scratch Kitchen from shareholders including P-E firms L Catterton and Oak Investment Partners for $780M.</li><li>DRI says Cheddar's, which has 165 locations across 28 states, will add a casual dining chain to its restaurant portfolio.</li><li>DRI expects the deal to be accretive to FY 2018 adjusted earnings by ~$0.12/share.</li><li>DRI, which also announced better than expected <a href=\"https://seekingalpha.com/news/3253683-darden-restaurants-plus-4-percent-boosting-profit-guidance\" target=\"_blank\">quarterly earnings</a> and guided FY 2017 earnings above consensus, <font color='green'>+3.7%</font>&nbsp;AH.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253701\" data-linked=\"Darden Restaurants buys Cheddar&#39;s Scratch Kitchen for $780M\" data-tweet=\"$DRI - Darden Restaurants buys Cheddar&#39;s Scratch Kitchen for $780M https://seekingalpha.com/news/3253701-darden-restaurants-buys-cheddars-scratch-kitchen-for-780m?source=tweet\" data-url=\"https://seekingalpha.com/news/3253701-darden-restaurants-buys-cheddars-scratch-kitchen-for-780m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253693\" data-ts=\"1490647885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSIX\" target=\"_blank\">PSIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253693-power-solutionsplus-54-after-chinese-firm-commits-to-60m-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Power Solutions +54% after Chinese firm commits to $60M investment</a></h4><ul>     <li>Power Solutions International (<a href='https://seekingalpha.com/symbol/PSIX' title='Power Solutions International, Inc.'>OTCPK:PSIX</a>) <font color='green'>+53.9%</font>&nbsp;AH after announcing that Weichai America, a Chinese designer and manufacturer of diesel engines, will <a href=\"https://seekingalpha.com/pr/16782034-power-solutions-international-announces-strategic-investment-collaboration-agreement-weichai\" target=\"_blank\">invest $60M in the company</a> through a combination of newly issued common shares and preferred shares.</li>     <li>As part of the agreement, Weichai will purchase ~2.73M newly issued common shares at $8.00/share and ~2.38M shares of series B convertible perpetual preferred stock, plus a warrant exercisable for more than 4M common shares; following the transactions, Weichai will own 40.7% of PSIX, with the warrants, if exercised, lifting ownership to 51%.</li>     <li>PSIX says it will use the $60M to refinance its debt structure, supporting its long-term growth objectives.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253693\" data-linked=\"Power Solutions +54% after Chinese firm commits to $60M investment\" data-tweet=\"$PSIX - Power Solutions +54% after Chinese firm commits to $60M investment https://seekingalpha.com/news/3253693-power-solutionsplus-54-after-chinese-firm-commits-to-60m-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3253693-power-solutionsplus-54-after-chinese-firm-commits-to-60m-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253692\" data-ts=\"1490647689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYRX\" target=\"_blank\">CYRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253692-cryoport-readies-equity-offering-shares-slump-25-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cryoport readies equity offering; shares slump 25% after hours</a></h4><ul><li>Cryoport (NASDAQ:<a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a>) <a href=\"https://seekingalpha.com/pr/16782049-cryoport-announces-proposed-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of common stock. Price, volume and terms have yet to be announced. Shares are down&nbsp;<font color='red'>25%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253692\" data-linked=\"Cryoport readies equity offering; shares slump 25% after hours\" data-tweet=\"$CYRX - Cryoport readies equity offering; shares slump 25% after hours https://seekingalpha.com/news/3253692-cryoport-readies-equity-offering-shares-slump-25-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3253692-cryoport-readies-equity-offering-shares-slump-25-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253689\" data-ts=\"1490647430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVH\" target=\"_blank\">EVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253689-evolent-health-shareholders-prepare-to-unload-7_5m-common-shares-shares-ease-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evolent Health shareholders prepare to unload 7.5M common shares; shares ease 1% after hours</a></h4><ul><li>Evolent Health (NYSE:<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health'>EVH</a>) slips&nbsp;<font color='red'>1%</font>&nbsp;after hours on average volume in response to its <a href=\"https://seekingalpha.com/pr/16782088-evolent-health-inc-announces-launch-secondary-public-offering-class-common-stock\" target=\"_blank\">announcement </a>of a public offering of 7.5M shares of Class A common stock. All shares are being sold by existing institutional shareholders. Underwriters over-allotment is an additional 1.125M shares. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253689\" data-linked=\"Evolent Health shareholders prepare to unload 7.5M common shares; shares ease 1% after hours\" data-tweet=\"$EVH - Evolent Health shareholders prepare to unload 7.5M common shares; shares ease 1% after hours https://seekingalpha.com/news/3253689-evolent-health-shareholders-prepare-to-unload-7_5m-common-shares-shares-ease-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3253689-evolent-health-shareholders-prepare-to-unload-7_5m-common-shares-shares-ease-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253686\" data-ts=\"1490647040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253686-red-hatplus-4_3-q4-2017-forecasted-revenues-over-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat +4.3%; Q4 2017, forecasted revenues over expectations</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3253674-red-hat-eps-line-beats-revenue\" target=\"_blank\">Q4 2017 results</a></strong> &ndash; revenue $629M (+15.7% Y/Y,&nbsp;<font color='green'>$10.24M above estimates</font>), EPS $0.61 (in line), subscription revenue $560M (+17% Y/Y), Application development-related and other emerging technology subscription revenue $125M (+40% Y/Y), year-end deferred revenue $2.1B (+20% Y/Y)</li><li><strong>Q1 2018 projections</strong> &ndash; revenue $643M-$650M (consensus $642.38M), EPS $0.52-$0.53 (consensus $0.59), operating margin 20%</li><li><strong>FY 2018 projections</strong> &ndash; revenue $2.72B-$2.76B (<a href=\"https://finance.yahoo.com/quote/RHT/analysts?p=RHT\" target=\"_blank\">consensus $2.71B</a>), EPS $2.60-$2.64 (consensus $2.59), operating margin 23.6%, operating cash flow $850M-$870M</li><li><strong>After hours</strong> &ndash; (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>) $85.70</li><li><a href=\"https://seekingalpha.com/pr/16782057-red-hat-reports-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Press release</a> / <a href=\"http://services.choruscall.com/links/rht170327X6ehT6W0.html\" target=\"_blank\">conference call</a> / <a href=\"https://investors.redhat.com/~/media/Files/R/Red-Hat-IR/documents/Q417-FX-summary.pdf\" target=\"_blank\">foreign exchange rates summary</a> /&nbsp;<a href=\"https://seekingalpha.com/filing/3475656\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253686\" data-linked=\"Red Hat +4.3%; Q4 2017, forecasted revenues over expectations\" data-tweet=\"$RHT - Red Hat +4.3%; Q4 2017, forecasted revenues over expectations https://seekingalpha.com/news/3253686-red-hatplus-4_3-q4-2017-forecasted-revenues-over-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3253686-red-hatplus-4_3-q4-2017-forecasted-revenues-over-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253685\" data-ts=\"1490646801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253685-tesaro-to-expand-development-program-for-parp-inhibitor-zejula-fda-approval-sends-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TESARO to expand development program for PARP inhibitor Zejula; FDA approval sends shares up 8% after hours</a></h4><ul><li>TESARO (NASDAQ:<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a>) <a href=\"https://seekingalpha.com/pr/16781988-tesaro-announces-expanded-development-program-niraparib-focused-treatment-front-line\" target=\"_blank\">announces </a>a substantial expansion of clinical development of just-FDA-approved niraparib (ZEJULA). It plans to initiate registration programs for metastatic ovarian, breast and lung cancers.</li><li>The FDA approved ZEJULA today for the maintenance treatment of ovarian cancer.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;after hours on robust volume. PARP competitor Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) is down&nbsp;<font color='red'>1%</font>&nbsp;on increased volume. AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) is up a fraction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253685\" data-linked=\"TESARO to expand development program for PARP inhibitor Zejula; FDA approval sends shares up 8% after hours\" data-tweet=\"$TSRO $TSRO $CLVS - TESARO to expand development program for PARP inhibitor Zejula; FDA approval sends shares up 8% after hours https://seekingalpha.com/news/3253685-tesaro-to-expand-development-program-for-parp-inhibitor-zejula-fda-approval-sends-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3253685-tesaro-to-expand-development-program-for-parp-inhibitor-zejula-fda-approval-sends-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253683\" data-ts=\"1490646519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRI\" target=\"_blank\">DRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253683-darden-restaurantsplus-4-after-boosting-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Darden Restaurants +4% after boosting profit guidance</a></h4><ul>     <li>Darden Restaurants (NYSE:<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a>) reports same-restaurant sales increased 0.9% in <a href=\"https://seekingalpha.com/pr/16782048-darden-restaurants-reports-fiscal-2017-third-quarter-results-increases-earnings-outlook-full\" target=\"_blank\">FQ3</a>&nbsp;vs. +0.3% consensus estimate. Six of seven chains reported a positive comp for the quarter.</li>     <li>Same-restaurant sales by brand: Olive Garden +1.4%, Longhorn Steakhouse +0.2%, Capital Grille +0.9%, Yard House -1.0%, Eddie V's +4.7%, Seasons 52 +0.8, Bahama Breeze +0.5%.</li> <li>\"We continued to gain market share as we outperformed industry same-restaurant sales by a considerable margin again this quarter,\" notes CEO Gene Lee.</li>     <li>Darden boosted its view for FY17 EPS to $3.95 to $4.00 vs. $3.87 to $3.97 prior. The company expects FY17 same-restaurant sales growth of 1.5%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253672-darden-restaurants-beats-0_04-beats-revenue\" target=\"_blank\">Darden Restaurants beats by $0.04, beats on revenue</a> (March 27)</li>      <li>DRI <font color='green'>+3.86%</font>&nbsp;AH to $78.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253683\" data-linked=\"Darden Restaurants +4% after boosting profit guidance\" data-tweet=\"$DRI - Darden Restaurants +4% after boosting profit guidance https://seekingalpha.com/news/3253683-darden-restaurantsplus-4-after-boosting-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3253683-darden-restaurantsplus-4-after-boosting-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253674\" data-ts=\"1490645845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253674-red-hat-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat EPS in-line, beats on revenue</a></h4><ul><li>Red Hat (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>): Q4 EPS of $0.61 in-line.</li><li>Revenue of $629M (+15.7% Y/Y) <font color='green'>beats by $10.24M</font>.</li><li>Shares <font color='green'>+3.25%</font>.</li><li><a href='https://seekingalpha.com/pr/16782057-red-hat-reports-fourth-quarter-fiscal-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253674\" data-linked=\"Red Hat EPS in-line, beats on revenue\" data-tweet=\"$RHT - Red Hat EPS in-line, beats on revenue https://seekingalpha.com/news/3253674-red-hat-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3253674-red-hat-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253672\" data-ts=\"1490645776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRI\" target=\"_blank\">DRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253672-darden-restaurants-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Darden Restaurants beats by $0.04, beats on revenue</a></h4><ul><li>Darden Restaurants (NYSE:<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a>): FQ3 EPS of $1.32 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $1.88B (+1.6% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+3.3%</font>.</li><li><a href='https://seekingalpha.com/pr/16782048-darden-restaurants-reports-fiscal-2017-third-quarter-results-increases-earnings-outlook-full'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253672\" data-linked=\"Darden Restaurants beats by $0.04, beats on revenue\" data-tweet=\"$DRI - Darden Restaurants beats by $0.04, beats on revenue https://seekingalpha.com/news/3253672-darden-restaurants-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3253672-darden-restaurants-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253670\" data-ts=\"1490645758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253670-fda-oks-tesaros-niraparib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs TESARO&#39;s niraparib</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16781991-tesaro-announces-u-s-fda-approval-zejula-niraparib-women-recurrent-ovarian-cancer\" target=\"_blank\">approves </a>TESARO's (NASDAQ:<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a>) PARP inhibitor niraparib, branded as ZEJULA, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemo.</li><li>ZEJULA is the first PARP inhibitor that does not require BRCA mutation or other biomarker testing. Market launch will commence in late April.</li><li><strong>Update</strong>: The company says it will release the price when it rolls out the product next month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253670\" data-linked=\"FDA OKs TESARO&#39;s niraparib\" data-tweet=\"$TSRO - FDA OKs TESARO&#39;s niraparib https://seekingalpha.com/news/3253670-fda-oks-tesaros-niraparib?source=tweet\" data-url=\"https://seekingalpha.com/news/3253670-fda-oks-tesaros-niraparib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253660\" data-ts=\"1490645170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STOR\" target=\"_blank\">STOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253660-capital-raise-for-store-capital-sharesminus-1_8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capital raise for STORE Capital; shares -1.8% after hours</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16782019-store-capital-commences-public-offering-common-stock\" target=\"_blank\">is selling 7.6M shares</a> of common stock, with underwriter greenshoe of 1.14M shares.</li><li>The net lease player is down 5% YTD, and 9% Y/Y.</li><li><a href='https://seekingalpha.com/symbol/STOR' title='STORE Capital'>STOR</a><font color='red'> -1.8%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3253660\" data-linked=\"Capital raise for STORE Capital; shares -1.8% after hours\" data-tweet=\"$STOR - Capital raise for STORE Capital; shares -1.8% after hours https://seekingalpha.com/news/3253660-capital-raise-for-store-capital-sharesminus-1_8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3253660-capital-raise-for-store-capital-sharesminus-1_8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253659\" data-ts=\"1490644734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNV\" target=\"_blank\">FNV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253659-franco-nevada-upgraded-to-buy-on-forecast-production-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Franco Nevada upgraded to Buy on forecast production boost</a></h4><ul><li>Franco Nevada (<a href='https://seekingalpha.com/symbol/FNV' title='Franco-Nevada Corporation'>FNV</a> <font color='green'>+2.8%</font>) is <a href=\"http://business.financialpost.com/investing/trading-desk/td-bullish-on-franco-nevada-upgrades-stock-to-buy-on-projection-for-production-boost\" target=\"_blank\">upgraded to Buy</a> from Hold with a $83 price target, raised from $71, at TD&nbsp;Securities, which expects the company's production to grow by 16% over the next five years.</li><li>The firm likes FNV's unique business model of helping finance projects in exchange for a portion of future revenues, instead of owning or operating mines; \"at a time when many gold producers are struggling to keep production flat, Franco&rsquo;s fully funded growth profile sets it apart,\" TD says.</li><li>&ldquo;Management noted that it expects to be active in writing stream agreements with base metal and precious metal miners as the next wave of mine development gets underway,\" the firm says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253659\" data-linked=\"Franco Nevada upgraded to Buy on forecast production boost\" data-tweet=\"$FNV - Franco Nevada upgraded to Buy on forecast production boost https://seekingalpha.com/news/3253659-franco-nevada-upgraded-to-buy-on-forecast-production-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3253659-franco-nevada-upgraded-to-buy-on-forecast-production-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253653\" data-ts=\"1490643986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253653-barclays-calls-out-staggering-traffic-drop-whole-foods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays calls out &#39;staggering&#39; traffic drop at Whole Foods</a></h4><ul> <li>There's another <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/27/whole-foods-the-traffic-declines-are-staggering-barclays-says/\" target=\"_blank\">shot</a> at Whole Foods (WFM) from a Wall Street firm and this one is a doozy.</li> <li>Barclays calls the magnitude of the traffic declines for the grocery store chain \"staggering\" in terms of raw numbers.</li> <li>\"We estimate ~9M-14M annual transactions left WFM in the last 6 quarters and <a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a>, which has meaningful overlap with WFM, is likely a direct beneficiary of WFM&rsquo;s share losses,\" reads the firm's note.</li> <li>Whole Foods has averaged a 3% loss in traffic over the last five quarters.</li> <li>Shares of Whole Foods are <font color='red'>down 1.38%</font> to $28.52. vs. a 52-week trading range of $27.67 to $35.58.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253653\" data-linked=\"Barclays calls out &#39;staggering&#39; traffic drop at Whole Foods\" data-tweet=\"$AMZN $AMZN $KR - Barclays calls out &#39;staggering&#39; traffic drop at Whole Foods https://seekingalpha.com/news/3253653-barclays-calls-out-staggering-traffic-drop-whole-foods?source=tweet\" data-url=\"https://seekingalpha.com/news/3253653-barclays-calls-out-staggering-traffic-drop-whole-foods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253652\" data-ts=\"1490643966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFX\" target=\"_blank\">NFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253652-newfield-exploration-sees-q1-production-topping-high-end-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newfield Exploration sees Q1 production topping high end of guidance</a></h4><ul><li>Newfield Exploration (<a href='https://seekingalpha.com/symbol/NFX' title='Newfield Exploration Co.'>NFX</a> <font color='green'>+3%</font>) is higher after forecasting Q1 2017 domestic production to average ~137.7K boe/day, or 3.5K boe/day <a href=\"https://seekingalpha.com/pr/16781202-newfield-announces-record-anadarko-basin-oil-well\" target=\"_blank\">better than the upper end of original guidance</a> of 132K-134.2K boe/day.<br></li><li>NFX also says its new, industry leading Burgess well in the heart of the company's 300K-plus net STACK acres  achieved a 24-hour flow rate of 2,931 boe/day and a 20-day  average rate of 2,492 boe/day.</li><li>Also, NFX&nbsp;CEO Lee Boothby tells Bloomberg the company will <a href=\"https://www.bloomberg.com/news/videos/2017-03-27/newfield-ceo-says-not-stressed-by-current-prices-video\" target=\"_blank\">move ahead with plans to expand drilling</a>  despite oil&rsquo;s recent slide, saying NFX can still generate double-digit growth and stay within cash flow at $50/bbl.</li><li>&ldquo;Right now, I&rsquo;m not feeling any stress in terms of prices,\" Boothby says, adding that while NFX may divest Bakken assets at some point, &ldquo;we don&rsquo;t have any need to sell today.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3253652\" data-linked=\"Newfield Exploration sees Q1 production topping high end of guidance\" data-tweet=\"$NFX - Newfield Exploration sees Q1 production topping high end of guidance https://seekingalpha.com/news/3253652-newfield-exploration-sees-q1-production-topping-high-end-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3253652-newfield-exploration-sees-q1-production-topping-high-end-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253651\" data-ts=\"1490643353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253651-doctors-see-no-clear-frontrunner-in-parp-race-tesaro-down-2-on-lack-of-leadership-of\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Doctors see no clear frontrunner in PARP race; TESARO down 2% on lack of leadership of niraparib</a></h4><ul><li>TESARO (<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='red'>-2.1%</font>) slips on below average volume on the heels of a survey of doctors conducted by Jefferies that revealed no clear winner among cancer immunotherapies called PARP inhibitors. Investors perceive the equivocation as a negative for niraparib.</li><li>Analyst Eun Yang says the poll of 29 oncologists revealed that other PARPs are \"more similar\" that previously assumed, undermining the Street's view that niraparib is the top dog. 10 of the 29 physicians viewed niraparib as the most effective while eight viewed the drugs as similar. Other PARP inhibitors are AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>&nbsp;<font color='green'>+1.6%</font>) olaparib (Lynparza)&nbsp;and Clovis Oncology's (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>&nbsp;<font color='red'>-3%</font>) rucaparib (Rubraca). AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='green'>+0.7%</font>) and Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+0.6%</font>) are working on candidates as well.</li><li>Yang's poll also suggests that a broad label \"may not translate into a big advantage.\" In maintenance therapy in BRCA-positive ovarian cancer (the largest expected opportunity), 30% of respondents favored olaparib, 25% niraparib and 20% rucaparib.</li><li>She adds that potential Clovis suitors will probably wait for further data and more insignt into AZN's recent data before making a move. She believes TSRO is already exchanging hands near the takeout price so there is significant downside risk for longs.</li><li>Source: The Fly</li><li>Nasdaq has halted trading pending news.</li><li><strong>Update</strong>: TSRO resumed trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253651\" data-linked=\"Doctors see no clear frontrunner in PARP race; TESARO down 2% on lack of leadership of niraparib\" data-tweet=\"$TSRO $TSRO $AZN - Doctors see no clear frontrunner in PARP race; TESARO down 2% on lack of leadership of niraparib https://seekingalpha.com/news/3253651-doctors-see-no-clear-frontrunner-in-parp-race-tesaro-down-2-on-lack-of-leadership-of?source=tweet\" data-url=\"https://seekingalpha.com/news/3253651-doctors-see-no-clear-frontrunner-in-parp-race-tesaro-down-2-on-lack-of-leadership-of\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253644\" data-ts=\"1490641214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253644-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SYX' title='Systemax Inc.'>SYX</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> MSDI <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SWIR' title='Sierra Wireless, Inc.'>SWIR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253644\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$SYX $SCON $DGLY - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3253644-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253644-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253643\" data-ts=\"1490641097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AU\" target=\"_blank\">AU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253643-colombia-location-of-potential-anglogold-project-votes-to-ban-mining\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Colombia location of potential AngloGold project votes to ban mining</a></h4><ul>     <li>Voters in Colombia's Tolima province approve a proposal to ban mining projects in their municipality</a>, raising questions about the future of AngloGold Ashanti's (<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+3.2%</font>) La Colosa mine, a $2B potential investment that could yield 28M&nbsp;oz. of gold.</li>     <li>AU has invested ~$900M in Colombia since 2006, including at La Colosa, the largest of its three projects in the country, but commodity producers have been increasingly concerned about recent court decisions banning exploration on land already awarded in concessions and giving local authorities greater power to reject mining projects.</li>     <li>AU has been exploring at the site in central Colombia for more than a decade.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253643\" data-linked=\"Colombia location of potential AngloGold project votes to ban mining\" data-tweet=\"$AU - Colombia location of potential AngloGold project votes to ban mining https://seekingalpha.com/news/3253643-colombia-location-of-potential-anglogold-project-votes-to-ban-mining?source=tweet\" data-url=\"https://seekingalpha.com/news/3253643-colombia-location-of-potential-anglogold-project-votes-to-ban-mining\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253642\" data-ts=\"1490640887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPWH\" target=\"_blank\">SPWH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253642-sportsmans-warehouse-lower-after-goldman-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sportsman&#39;s Warehouse lower after Goldman cut</a></h4><ul> <li>Sportsman's Warehouse (<a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-5.4%</font>) trades lower after Goldman Sachs drops the retailer to a Neutral rating after having it slotted at Buy.</li> <li>The firm cites a lack of positive catalysts for Sportsman's Warehouse and sees liquidity constraints playing in.</li> <li>Goldman cuts its <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Sportsmans+Warehouse+%28SPWH%29+to+Neutral+Citing+Lack+Of+Catalysts/12706787.html\" target=\"_blank\">price target</a> by 24% to $6.50 off estimates of FY17 EPS of $0.68 and FY18 EPS of $0.63.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3253642\" data-linked=\"Sportsman&#39;s Warehouse lower after Goldman cut\" data-tweet=\"$SPWH - Sportsman&#39;s Warehouse lower after Goldman cut https://seekingalpha.com/news/3253642-sportsmans-warehouse-lower-after-goldman-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3253642-sportsmans-warehouse-lower-after-goldman-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253636\" data-ts=\"1490638612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253636-viacom-officially-taps-gianopulos-to-lead-paramount\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom officially taps Gianopulos to lead Paramount</a></h4><ul>   <li>As expected, Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+3.5%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='green'>+2%</font>) has installed Jim Gianopulos as <a href=\"https://seekingalpha.com/pr/16781907-viacom-names-jim-gianopulos-chairman-chief-executive-officer-paramount-pictures\" target=\"_blank\">chairman and chief executive officer</a> at Paramount Pictures, where he'll replace ousted chief Brad Grey.</li>    <li>The move fills one of two gaps atop major Hollywood studios. Sony Pictures is still <a href=\"https://seekingalpha.com/news/3253598-sony-pictures-interviews-warner-bros-film-chief-top-job\" target=\"_blank\">on the hunt for a replacement</a> for outgoing chief Michael Lynton.</li>    <li>Gianopulos is a veteran of Fox, previously serving for 16 years as chairman/CEO of Fox Filmed Entertainment, and before that as president of Twentieth Century Fox International.</li>    <li>He'll oversee film and TV operations worldwide in all facets for Paramount, including production, marketing and distribution.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253636\" data-linked=\"Viacom officially taps Gianopulos to lead Paramount\" data-tweet=\"$VIA $VIA $VIAB - Viacom officially taps Gianopulos to lead Paramount https://seekingalpha.com/news/3253636-viacom-officially-taps-gianopulos-to-lead-paramount?source=tweet\" data-url=\"https://seekingalpha.com/news/3253636-viacom-officially-taps-gianopulos-to-lead-paramount\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253634\" data-ts=\"1490637670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253634-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+75%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/KGJI' title='KINGOLD JEWELRY'>KGJI</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FRAC' title='Keane Group'>FRAC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ACH' title='Aluminum Corporation of China Ltd'>ACH</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/AXAS' title='Abraxas Petroleum Corporation'>AXAS</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253634\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$GBR $DELT-OLD $KGJI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3253634-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253634-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253628\" data-ts=\"1490636046\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGF.A\" target=\"_blank\">LGF.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253628-disneys-beauty-and-beast-among-fastest-films-to-317m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney&#39;s &#39;Beauty and the Beast&#39; among fastest films to $317M</a></h4><ul>   <li>A second massive weekend for <i>Beauty and the Beast</i> (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='green'>+0.2%</font>) kept it atop a strong box office, holding off a challenge from teen-hero challenger <i>Power Rangers</i> (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a> <font color='green'>+2.6%</font>; <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a> <font color='green'>+3.2%</font>).</li>    <li>The Disney live-action remake drew $88.3M in early estimates, which along with strong weekday business brought its domestic take to $316.95M cumulative (one of the fastest films to get there). Strong Sunday numbers a week ago boosted its final take and might this week as well.</li>    <li>Foreign results continue to be strong as well, giving the picture a $690.3M cumulative worldwide gross.</li>    <li><i>Power Rangers</i> was a distant second with $40.5M, while <i>Kong: Skull Island</i> (<a href=\"http://seekingalpha.com/symbol/TWX\" target=\"_blank\">TWX</a> <font color='red'>-0.3%</font>) hung in at No. 3 with $14.4M. Strong global results have boosted <i>Kong's</i> worldwide take to cumulative $392M in its third week of release.</li>    <li>In other new releases, space thriller <i>Life</i> (<a href=\"http://seekingalpha.com/symbol/SNE\" target=\"_blank\">SNE</a> <font color='green'>+0.8%</font>) settled at No. 4 with a disappointing $12.6M, while TV-series adaptation <i>CHIPS</i> (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>) was No. 7 with just $7.6M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253628\" data-linked=\"Disney&#39;s &#39;Beauty and the Beast&#39; among fastest films to $317M\" data-tweet=\"$LGF.A $LGF.A $LGF.B - Disney&#39;s &#39;Beauty and the Beast&#39; among fastest films to $317M https://seekingalpha.com/news/3253628-disneys-beauty-and-beast-among-fastest-films-to-317m?source=tweet\" data-url=\"https://seekingalpha.com/news/3253628-disneys-beauty-and-beast-among-fastest-films-to-317m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253626\" data-ts=\"1490635995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASPS\" target=\"_blank\">ASPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253626-altisource-portfolio-up-another-6-short-squeeze-story-gets-legs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altisource Portfolio up another 6% as short squeeze story gets legs</a></h4><ul><li>S3 Partners'&nbsp;Ihor Dusaniwsky tells Bloomberg, that short interest is 31% of the market cap and a full 59% of the float vs. 21% and 39%, respectively, one month ago.</li><li>New borrows today are being charged as much as 100%, while outstanding shorts are paying 60%. He sees rates on existing borrows rising to 75% by the end of the week.</li><li>Meanwhile on Seeking Alpha, <a href=\"https://seekingalpha.com/article/4058177-big-short-squeeze-altisource\" target=\"_blank\">contributor Amit Shamir paints</a> a similarly dire picture for the shorts.</li><li>Altisource Portfolio Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/ASPS' title='Altisource Portfolio Solutions SA'>ASPS</a>)&nbsp;<font color='green'>up 6.4%</font>&nbsp;today, and&nbsp;<font color='green'>up 23%</font>&nbsp;in the last three sessions.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253385-shorts-press-bets-altisource-portfolio-solutions\" target=\"_blank\">Shorts press bets in Altisource Portfolio Solutions</a> (March 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252825-short-squeeze-building-altisource-portfolio-solutions\" target=\"_blank\">Short squeeze building in Altisource Portfolio Solutions?</a> (March 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253626\" data-linked=\"Altisource Portfolio up another 6% as short squeeze story gets legs\" data-tweet=\"$ASPS - Altisource Portfolio up another 6% as short squeeze story gets legs https://seekingalpha.com/news/3253626-altisource-portfolio-up-another-6-short-squeeze-story-gets-legs?source=tweet\" data-url=\"https://seekingalpha.com/news/3253626-altisource-portfolio-up-another-6-short-squeeze-story-gets-legs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253624\" data-ts=\"1490634894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TI\" target=\"_blank\">TI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253624-former-ferrari-chairman-in-lead-to-chair-telecom-italia-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Former Ferrari chairman in lead to chair Telecom Italia board</a></h4><ul>   <li>Luca Cordero Di Montezemolo -- former chairman of Ferrari, and currently chairman of Alitalia -- is a <a href=\"https://www.bloomberg.com/news/articles/2017-03-27/ferrari-ex-boss-said-to-be-telecom-italia-chairman-candidate-j0s30fhz\" target=\"_blank\">front-runner to take over the board</a> at Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color='green'>+2.1%</font>), Bloomberg reports.</li>    <li>That impetus comes from top shareholder Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color='green'>+1.4%</font>), which might yet keep on Giuseppe Recchi as chairman. But switching to Montezemolo could get more power to TI CEO Flavio Cattaneo.</li>    <li>Cattaneo was previously CEO at Montezemolo's high-speed rail company NTV. Montezemolo is planning to leave Alitalia's chairmanship once funding for a new restructuring plan there is approved.</li>    <li>Telecom Italia investors face an April 9 deadline for board-slate proposals, ahead of the May 4 annual meeting.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253624\" data-linked=\"Former Ferrari chairman in lead to chair Telecom Italia board\" data-tweet=\"$TI $TI $VIVHY - Former Ferrari chairman in lead to chair Telecom Italia board https://seekingalpha.com/news/3253624-former-ferrari-chairman-in-lead-to-chair-telecom-italia-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3253624-former-ferrari-chairman-in-lead-to-chair-telecom-italia-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253619\" data-ts=\"1490634026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253619-stocks-erase-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks erase most losses</a></h4><ul><li>Down sizably in the early going, the major averages have returned to little-changed on the session, with the Nasdaq even poking its head into green territory.</li><li>Leading to the downside earlier, banks have about halved their losses, with the KBE&nbsp;<font color='red'>down 1.1%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253619\" data-linked=\"Stocks erase most losses\" data-tweet=\"Stocks erase most losses https://seekingalpha.com/news/3253619-stocks-erase-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3253619-stocks-erase-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253614\" data-ts=\"1490633329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253614-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='green'>+79%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+75%</font>. IPXL <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/SYX' title='Systemax Inc.'>SYX</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+18%</font>. ITUS <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FOMX' title='Foamix Pharmaceuticals'>FOMX</a> <font color='red'>-45%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='red'>-11%</font>. MSDI <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SWIR' title='Sierra Wireless, Inc.'>SWIR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/XBIT' title='Xbiotech'>XBIT</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253614\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$APOP $GBR $AMRX - Midday Gainers / Losers https://seekingalpha.com/news/3253614-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3253614-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253588\" data-ts=\"1490632614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTNB\" target=\"_blank\">MTNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253588-matinas-biopharma-reports-positive-topline-data-from-phase-1-study-mat2501-sharesplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matinas BioPharma reports positive topline data from phase 1 study\nMAT2501; Shares +4%</a></h4><ul>     <li>Matinas BioPharma Holdings (<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a>&nbsp;<font color='green'>+4%</font>) today <a href=\"https://seekingalpha.com/pr/16781133-matinas-biopharma-reports-positive-topline-data-phase-1-study-mat2501\" target=\"_blank\">reported positive topline data from its Phase 1 single-ascending dose study of MAT2501</a> in healthy volunteers.</li>     <li>MAT2501 was well-tolerated with no serious adverse events reported in the study.</li>     <li>Oral administration of MAT2501 at all three doses yielded blood levels of amikacin that were well below the safety levels recommended for IV-administered amikacin, and consistent with the results from preclinical studies of MAT2501.</li>     <li>CEO Roelof Rongen: \"We are very pleased with the outcome of our initial Phase 1 study of MAT2501 and believe that the results of this study support the further development of MAT2501 for the treatment of NTM infections as a first indication, &ldquo;We have shown that the oral administration of MAT2501 at doses we expect to use with patients is well tolerated and yields blood levels well below the labeled safety limits for amikacin. Our plan is to continue to drive development of this important product forward in such a way as to maximize the opportunity we might have in developing and potentially receiving FDA-approval for what we believe will be the first orally-available aminoglycoside.&rdquo;</li>     <li>See important <a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253588\" data-linked=\"Matinas BioPharma reports positive topline data from phase 1 study\nMAT2501; Shares +4%\" data-tweet=\"$MTNB - Matinas BioPharma reports positive topline data from phase 1 studyMAT2501; Shares +4% https://seekingalpha.com/news/3253588-matinas-biopharma-reports-positive-topline-data-from-phase-1-study-mat2501-sharesplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3253588-matinas-biopharma-reports-positive-topline-data-from-phase-1-study-mat2501-sharesplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253609\" data-ts=\"1490631745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXAS\" target=\"_blank\">EXAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253609-aetna-adds-cologuard-to-covered-list-exact-up-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aetna adds Cologuard to covered list; Exact up 7%</a></h4><ul><li>Exact Sciences (<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='green'>+7.3%</font>) perks up on increased volume on the <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/27/why-exact-sciences-is-soaring/?mod=BOL_hp_blog_stw\" target=\"_blank\">news</a> that Aetna has <a href=\"http://www.aetna.com/cpb/medical/data/500_599/0516.html\" target=\"_blank\">added </a>Cologuard to its list of covered tests for colorectal cancer screening, adding commercial coverage to the previously announced Medicare Advantage inclusion.</li><li>Aetna currently covers 18.6M lives.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253609\" data-linked=\"Aetna adds Cologuard to covered list; Exact up 7%\" data-tweet=\"$EXAS - Aetna adds Cologuard to covered list; Exact up 7% https://seekingalpha.com/news/3253609-aetna-adds-cologuard-to-covered-list-exact-up-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3253609-aetna-adds-cologuard-to-covered-list-exact-up-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253611\" data-ts=\"1490631727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253611-steel-prices-may-peak-near-term-on-cost-deflation-morgan-stanley-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel prices may peak near-term on cost deflation, Morgan Stanley says</a></h4><ul><li>Steel prices (<a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a> <font color='red'>-1.6%</font>) could see &ldquo;tactical bumps in the road&rdquo; in the near-term as  a meaningful drop in the steel cost curve likely will create <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/27/u-s-steel-no-really-steels-gonna-be-just-fine-morgan-stanley-says/\" target=\"_blank\">additional  headwinds for global prices</a>, ultimately impacting the U.S. market, Morgan  Stanley analysts say.</li><li>The firm nevertheless says any cost deflation related price weakness should have little  impact on the mid-cycle margin outlook, and while price cycles will never disappear, it believes structural improvements in the form of trade barriers and China supply side reform should allow margins to remain higher on average going forward.</li><li>Stanley recommends buying steel stocks on any weakness, and sees Nucor (<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='red'>-1.4%</font>), Steel Dynamics (<a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='red'>-1.6%</font>) and U.S. Steel (<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='red'>-4.2%</font>) as its top picks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253611\" data-linked=\"Steel prices may peak near-term on cost deflation, Morgan Stanley says\" data-tweet=\"$NUE $SLX $NUE - Steel prices may peak near-term on cost deflation, Morgan Stanley says https://seekingalpha.com/news/3253611-steel-prices-may-peak-near-term-on-cost-deflation-morgan-stanley-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3253611-steel-prices-may-peak-near-term-on-cost-deflation-morgan-stanley-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253607\" data-ts=\"1490630494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253607-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/BTN' title='Ballantyne Strong, Inc.'>BTN</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253607\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NAKD $BTN $GIII - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3253607-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253607-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253604\" data-ts=\"1490630247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253604-fitbit-launches-alta-hr-worldwide-sharesplus-4_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit launches Alta HR worldwide; shares +4.9%</a></h4><ul>   <li>Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) is riding high, <font color='green'>up 4.9%</font>, on <a href=\"https://seekingalpha.com/pr/16781470-fitbit-announces-global-availability-alta-hr-world-s-slimmest-fitness-wristband-continuous\" target=\"_blank\">global launch day</a> for its Alta HR wearable, which it says is the slimmest wristband with continuous heart rate tracking. It's early, as the company expected an April launch.</li>    <li>New software features planned for launch, including Sleep Stages and Sleep Insights, will be available this week in the Fitbit app (Windows, iOS/Android).</li>    <li>The company's pricing the Alta HR at $149.95 with its standard band, with upsell accessory bands ranging from $29.95-$179.95 additional.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253604\" data-linked=\"Fitbit launches Alta HR worldwide; shares +4.9%\" data-tweet=\"$FIT - Fitbit launches Alta HR worldwide; shares +4.9% https://seekingalpha.com/news/3253604-fitbit-launches-alta-hr-worldwide-sharesplus-4_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3253604-fitbit-launches-alta-hr-worldwide-sharesplus-4_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253601\" data-ts=\"1490630102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPIX\" target=\"_blank\">IPIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253601-cellceutixs-brilacidin-shows-encouraging-treatment-effect-in-om-patients-in-mid-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellceutix&#39;s Brilacidin shows encouraging treatment effect in OM patients in mid-stage study; shares ahead 3%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16781642-cellceutix-reports-encouraging-interim-analysis-phase-2-drug-candidate-brilacidin-severe-oral\" target=\"_blank\">Preliminary data</a> from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02324335?term=CTIX-BRI-205&amp;rank=1\" target=\"_blank\">CTIX-BRI-205</a>, assessing Cellceutix's (CTIX <font color='green'>+2.6%</font>) Brilacidin oral rinse for the prevention and control on oral mucositis &#40;OM&#41; in head and neck cancer patients receiving chemoradiation showed a significant treatment benefit.</li><li>The incidence of severe OM [WHO Grade &gt;3 (oral ulcers, liquid diet only)] in the treatment group was 22.2% (n=2/9) compared to 70% (n=7/10) for placebo. The mean duration of severe OM also favored Brilacidin, 10.5 days vs. 14.0 days.</li><li>According to ClinicalTrials.gov, the estimated study completion date is December.</li><li>Brilacidin is a member of a new class of antibiotics called&nbsp;<a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820767/\" target=\"_blank\">defensin-mimetics</a>&nbsp;which are modeled after host defense proteins. These are the \"front line\" of defense in the human immune system.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253601\" data-linked=\"Cellceutix&#39;s Brilacidin shows encouraging treatment effect in OM patients in mid-stage study; shares ahead 3%\" data-tweet=\"$IPIX - Cellceutix&#39;s Brilacidin shows encouraging treatment effect in OM patients in mid-stage study; shares ahead 3% https://seekingalpha.com/news/3253601-cellceutixs-brilacidin-shows-encouraging-treatment-effect-in-om-patients-in-mid-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3253601-cellceutixs-brilacidin-shows-encouraging-treatment-effect-in-om-patients-in-mid-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253594\" data-ts=\"1490628508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOS\" target=\"_blank\">KTOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253594-defense-names-mull-future-of-trump-agenda-after-healthcare-failure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Defense names mull future of Trump agenda after healthcare failure</a></h4><ul><li>The entire agenda of the Trump administration - including boosted defense spending and lower taxes - is being called into question after the GOP's failure on healthcare.</li><li>Among the defense movers: Kratos (<a href='https://seekingalpha.com/symbol/KTOS' title='Kratos Defense & Security Solutions, Inc.'>KTOS</a> <font color='red'>-1.5%</font>), Northrop Grumman (<a href='https://seekingalpha.com/symbol/NOC' title='Northrop Grumman Corporation'>NOC</a> <font color='red'>-0.6%</font>), Mercury Systems (<a href='https://seekingalpha.com/symbol/MRCY' title='Mercury Systems, Inc.'>MRCY</a> <font color='red'>-4.2%</font>), General Dynamics (<a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a> <font color='red'>-1.5%</font>), Lockheed Martin (<a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a> <font color='red'>-0.4%</font>), L3 Technologies (<a href='https://seekingalpha.com/symbol/LLL' title='L3 Technologies'>LLL</a> <font color='red'>-1.5%</font>), Textron (<a href='https://seekingalpha.com/symbol/TXT' title='Textron Inc'>TXT</a> <font color='red'>-0.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253594\" data-linked=\"Defense names mull future of Trump agenda after healthcare failure\" data-tweet=\"$KTOS $KTOS $NOC - Defense names mull future of Trump agenda after healthcare failure https://seekingalpha.com/news/3253594-defense-names-mull-future-of-trump-agenda-after-healthcare-failure?source=tweet\" data-url=\"https://seekingalpha.com/news/3253594-defense-names-mull-future-of-trump-agenda-after-healthcare-failure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253592\" data-ts=\"1490628230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KATE\" target=\"_blank\">KATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253592-kate-spade-coach-deal-expected-around-corner\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kate Spade-Coach deal expected around the corner</a></h4><ul> <li>Kate Spade (NYSE:<a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a>) is <font color='green'>up 1.92%</font> after The Business of Fashion <a href=\"https://www.businessoffashion.com/articles/news-analysis/coach-said-to-be-readying-kate-spade-buy\" target=\"_blank\">reports</a> that an acquisition by Coach (COH <font color='green'>+1.6%</font>) could occur within weeks.</li> <li>Shares of Kate are already up 63% over the last 90 days off of ongoing M&amp;A speculation. Coash is up 15% same time period.</li> <li>\"There are synergies in sourcing from a leather perspective, and synergies in terms of global development,\" notes Cowen and Company's Oliver Chen on the potential combination.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253592\" data-linked=\"Kate Spade-Coach deal expected around the corner\" data-tweet=\"$KATE $KATE $TPR - Kate Spade-Coach deal expected around the corner https://seekingalpha.com/news/3253592-kate-spade-coach-deal-expected-around-corner?source=tweet\" data-url=\"https://seekingalpha.com/news/3253592-kate-spade-coach-deal-expected-around-corner\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253584\" data-ts=\"1490627105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONDK\" target=\"_blank\">ONDK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253584-ondeck-deal-not-likely-bloomberg-gadfly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OnDeck deal not likely - Bloomberg GadFly</a></h4><ul><li>The stock got a quick pop on Thursday morning on a report that rival Kabbage was interested in purchasing, but the chances of deal don't seem particularly realistic, <a href=\"https://www.bloomberg.com/gadfly/articles/2017-03-23/ondeck-capital-holders-hoping-for-a-sale-may-have-to-wait?utm_content=gadfly&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_medium=social&amp;cmpid%3D=socialflow-twitter-gadfly\" target=\"_blank\">writes Gillian Tan</a>.</li><li>The most obvious reason is that OnDeck's (NYSE:<a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a>) earliest investors - who continue to own more than 45% of the company - are going to want far more than the standard takeout premium given that the stock trades at less than 25% of its IPO price.</li><li>Some other type of merger deal - in which OnDeck investors might be able to participate in future success - may make more sense. Trouble is currency: As a private company, Kabbage can't easily offer shares. A reverse merger seems unlikely as Kabbage has already raised money privately.</li><li>For now, the way forward for OnDeck seems to be delivering on its long-term promises to investors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253584\" data-linked=\"OnDeck deal not likely - Bloomberg GadFly\" data-tweet=\"$ONDK - OnDeck deal not likely - Bloomberg GadFly https://seekingalpha.com/news/3253584-ondeck-deal-not-likely-bloomberg-gadfly?source=tweet\" data-url=\"https://seekingalpha.com/news/3253584-ondeck-deal-not-likely-bloomberg-gadfly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253554\" data-ts=\"1490626921\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253554-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='green'>+76%</font>. IPXL <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FOMX' title='Foamix Pharmaceuticals'>FOMX</a> <font color='red'>-43%</font>. <a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a> <font color='red'>-8%</font>. NEOT <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ITGR' title='Integer Holdings Corporation'>ITGR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253554\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$APOP $AMRX $RGLS - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3253554-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3253554-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253579\" data-ts=\"1490626028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WAGE\" target=\"_blank\">WAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253579-wageworksminus-7-after-healthcare-bill-crumble\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wageworks -7% after healthcare bill crumble</a></h4><ul><li>Wageworks (<a href='https://seekingalpha.com/symbol/WAGE' title='WageWorks, Inc.'>WAGE</a> <font color='red'>-6.8%</font>) should be a casualty from the failure to pass Trumpcare, says Wells Fargo, downgrading to Market Perform from Outperform.</li><li>The stock was a high-riser post-election as HSAs were expected to be a big part of the Trump health care plan. Shares are now&nbsp;<font color='red'>down about 14%</font>&nbsp;since it began coming clear about 10 days ago that the bill was headed for defeat.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3253579\" data-linked=\"Wageworks -7% after healthcare bill crumble\" data-tweet=\"$WAGE - Wageworks -7% after healthcare bill crumble https://seekingalpha.com/news/3253579-wageworksminus-7-after-healthcare-bill-crumble?source=tweet\" data-url=\"https://seekingalpha.com/news/3253579-wageworksminus-7-after-healthcare-bill-crumble\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253574\" data-ts=\"1490624898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253574-sears-holdings-breaks-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears Holdings breaks higher</a></h4><ul> <li>Shares of Sears Holdings (SHLD) are <font color='green'>up 9.29%</font> to trade at their highest level since the company warned on its financial status early last week.</li> <li>Some insider buying action from Eddie Lampert could be influencing trading on the company.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252784-sears-minus-15-percent-going-concern-warning\" target=\"_blank\">Sears -15% after 'going concern' warning</a> (March 22)</li> <li><a href=\"https://seekingalpha.com/filing/3474804\" target=\"_blank\">SEC Form 4</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253574\" data-linked=\"Sears Holdings breaks higher\" data-tweet=\"$SHLDQ - Sears Holdings breaks higher https://seekingalpha.com/news/3253574-sears-holdings-breaks-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3253574-sears-holdings-breaks-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253572\" data-ts=\"1490624617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGR\" target=\"_blank\">NTGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253572-netgearminus-4-off-wall-street-issues-new-sell-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netgear -4% as Off Wall Street issues new Sell rating</a></h4><ul>   <li>Netgear (NASDAQ:<a href='https://seekingalpha.com/symbol/NTGR' title='NETGEAR, Inc.'>NTGR</a>) has <font color='red'>slipped 4%</font> after getting hit with a new Sell rating at Off Wall Street.</li>    <li>The firm expects disappointing results from Netgear as the company faces tougher competition.</li>    <li>It's set a price target of $36, implying a further 27% downside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253572\" data-linked=\"Netgear -4% as Off Wall Street issues new Sell rating\" data-tweet=\"$NTGR - Netgear -4% as Off Wall Street issues new Sell rating https://seekingalpha.com/news/3253572-netgearminus-4-off-wall-street-issues-new-sell-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3253572-netgearminus-4-off-wall-street-issues-new-sell-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253569\" data-ts=\"1490624503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253569-bank-correction-leads-retreat-in-markets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank correction leads retreat in markets</a></h4><ul><li>The major indexes are&nbsp;<font color='red'>down just 0.6%</font>, but the <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> and <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> are each&nbsp;<font color='red'>lower by well over 2%</font>&nbsp;in early action. This just in ... both of these banking indexes are&nbsp;<font color='red'>off 10%</font>&nbsp;this month.</li><li>The broader <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> is&nbsp;<font color='red'>down 1.4%</font>&nbsp;today, and&nbsp;<font color='red'>5.5%</font>&nbsp;for the month.</li><li>Bank investors may be adjusting the odds of regulatory reform given the GOP's healthcare failure. There's also interest rates, and the curve continues to flatten with the 10-year yield down another six basis points to 2.36%.</li><li>Morgan Stanley is&nbsp;<font color='red'>down 4%</font>&nbsp;after Charles Peabody <a href=\"https://seekingalpha.com/news/3253536-morgan-stanley-minus-2_5-percent-downgrade-sell\" target=\"_blank\">downgraded to Sell</a>, citing a lofty valuation following a 60% Y/Y run higher.</li><li>Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-2.4%</font>), Goldman (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-2.4%</font>), Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='red'>-0.9%</font>), Regions (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='red'>-2.5%</font>), U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-1.7%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-2.2%</font>), PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='red'>-2.1%</font>), Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='red'>-2.4%</font>), SunTrust (<a href='https://seekingalpha.com/symbol/STI' title='SunTrust Banks, Inc.'>STI</a> <font color='red'>-2.5%</font>), M&amp;T (<a href='https://seekingalpha.com/symbol/MTB' title='M&T Bank Corporation'>MTB</a> <font color='red'>-2.1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253569\" data-linked=\"Bank correction leads retreat in markets\" data-tweet=\"$BAC $KRE $KBE - Bank correction leads retreat in markets https://seekingalpha.com/news/3253569-bank-correction-leads-retreat-in-markets?source=tweet\" data-url=\"https://seekingalpha.com/news/3253569-bank-correction-leads-retreat-in-markets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253568\" data-ts=\"1490624354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFT\" target=\"_blank\">WFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253568-schlumberger-weatherford-launch-fracking-jv-to-rival-halliburton\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schlumberger, Weatherford launch fracking JV to rival Halliburton</a></h4><ul>     <li>Weatherford (<a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a> <font color='green'>+8.5%</font>) is an unusual gainer among oil and gas stocks in early trading following news of a <a href=\"https://seekingalpha.com/pr/16780816-weatherford-schlumberger-form-onestim-joint-venture\" target=\"_blank\">fracking joint venture</a> with Schlumberger (<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color='red'>-1%</font>) that will rival Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color='red'>-3.2%</font>) in size.</li>     <li>SLB will own 70% and be the operator of the OneStim hydraulic fracturing partnership, while WFT will own 30% and receive a one-time $535M cash payment.</li>     <li>The companies say the partnership will <a href=\"http://fuelfix.com/blog/2017/03/24/schlumberger-weatherford-to-form-joint-venture/\" target=\"_blank\">combine</a> SLB&rsquo;s large fracking fleet of  high-horsepower pumps and WFT technologies used to stimulate  multiple separate horizontal zones within shale wells.</li>     <li>The new JV <a href=\"https://www.bloomberg.com/news/articles/2017-03-24/new-schlumberger-venture-takes-aim-at-toppling-king-of-fracking\" target=\"_blank\">will bring SLB closer to HAL</a>, which has a total fleet of fracking pumps that add up to 3M horsepower, according to oilfield consultant Spears &amp; Associates; SLB currently has ~2M hp and WFT has ~800K-1M hp.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253568\" data-linked=\"Schlumberger, Weatherford launch fracking JV to rival Halliburton\" data-tweet=\"$WFT $WFTIQ $SLB - Schlumberger, Weatherford launch fracking JV to rival Halliburton https://seekingalpha.com/news/3253568-schlumberger-weatherford-launch-fracking-jv-to-rival-halliburton?source=tweet\" data-url=\"https://seekingalpha.com/news/3253568-schlumberger-weatherford-launch-fracking-jv-to-rival-halliburton\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253565\" data-ts=\"1490623631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253565-synergy-pharma-files-u-s-marketing-application-for-expanded-use-of-trulance-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synergy Pharma files U.S. marketing application for expanded use of Trulance; shares ahead 1%</a></h4><ul><li>Synergy Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='green'>+0.7%</font>) <a href=\"https://seekingalpha.com/pr/16781164-synergy-pharmaceuticals-submits-supplemental-new-drug-application-snda-trulance-plecanatide\" target=\"_blank\">files</a> a supplemental New Drug Application (sNDA) with the FDA seeking approval of TRULANCE (plecanatide) to treat adults with irritable bowel syndrome with constipation (IBS-C).</li><li>The FDA approved the guanylate cyclase-C agonist in January for the treatment of adults with chronic ideopathic constipation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253565\" data-linked=\"Synergy Pharma files U.S. marketing application for expanded use of Trulance; shares ahead 1%\" data-tweet=\"$SGYP $SGYP-OLD - Synergy Pharma files U.S. marketing application for expanded use of Trulance; shares ahead 1% https://seekingalpha.com/news/3253565-synergy-pharma-files-u-s-marketing-application-for-expanded-use-of-trulance-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3253565-synergy-pharma-files-u-s-marketing-application-for-expanded-use-of-trulance-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>79&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253563\" data-ts=\"1490623387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWIR\" target=\"_blank\">SWIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253563-sierra-wirelessminus-8_2-raymond-james-cuts-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sierra Wireless -8.2% as Raymond James cuts to Neutral</a></h4><ul>   <li>Sierra Wireless (NASDAQ:<a href='https://seekingalpha.com/symbol/SWIR' title='Sierra Wireless, Inc.'>SWIR</a>) is <font color='red'>8.2% lower</font> after getting its rating cut to Market Perform by Raymond James.</li>    <li>Shares had hit a 52-week high of $30.60 on Thursday. Raymond James' Steven Li had rated the stock an Outperform previously.</li>    <li>Li has raised the price target to $30 from a previous $23.50 -- so about 10% upside from today's now-lowered price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253563\" data-linked=\"Sierra Wireless -8.2% as Raymond James cuts to Neutral\" data-tweet=\"$SWIR - Sierra Wireless -8.2% as Raymond James cuts to Neutral https://seekingalpha.com/news/3253563-sierra-wirelessminus-8_2-raymond-james-cuts-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3253563-sierra-wirelessminus-8_2-raymond-james-cuts-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253560\" data-ts=\"1490623210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253560-new-chief-insys-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief at Insys; shares up 1%</a></h4><ul><li>Insys Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+0.8%</font>) perks up on the <a href=\"https://seekingalpha.com/pr/16781088-insys-announces-saeed-motahari-become-president-chief-executive-officer-member-board\" target=\"_blank\">news </a>that Saeed Motahari will become President &amp; CEO on April 17. He joins the firm from Purdue Pharma where he was Chief Commercial Officer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253560\" data-linked=\"New chief at Insys; shares up 1%\" data-tweet=\"$INSY $INSYQ - New chief at Insys; shares up 1% https://seekingalpha.com/news/3253560-new-chief-insys-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3253560-new-chief-insys-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253556\" data-ts=\"1490622669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIR\" target=\"_blank\">PIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253556-amazon-shadow-hangs-over-furniture-and-home-furnishing-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon shadow hangs over furniture and home furnishing stocks</a></h4><ul> <li>Select furniture store and home furnishing stocks are down in early trading more than broad market averages. A weekend report that Amazon may open up stores to compete directly in the sector could be swaying sentiment.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253433-amazon-looks-disrupt-retail-store-concept\" target=\"_blank\">Amazon looks to disrupt retail store concept</a> (March 25)</li> <li>Movers: Pier 1 Imports (NYSE:<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a>) <font color='red'>-2.18%</font>. RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>) <font color='red'>-3.03%</font>. Bed, Bath &amp; Beyond (NASDAQ:<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>) <font color='red'>-1.30%</font>. Kirkland's (NASDAQ:<a href='https://seekingalpha.com/symbol/KIRK' title='Kirkland&#39;s, Inc.'>KIRK</a>) <font color='red'>-1.12%</font>. Haverty Furniture (NYSE:<a href='https://seekingalpha.com/symbol/HVT' title='Haverty Furniture Companies Inc.'>HVT</a>) <font color='red'>-1.10%</font>. The Container Store (NYSE:<a href='https://seekingalpha.com/symbol/TCS' title='The Container Store Group, Inc.'>TCS</a>)&nbsp;<font color='red'>-1.52%</font>.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3253556\" data-linked=\"Amazon shadow hangs over furniture and home furnishing stocks\" data-tweet=\"$PIR $PIR $RH - Amazon shadow hangs over furniture and home furnishing stocks https://seekingalpha.com/news/3253556-amazon-shadow-hangs-over-furniture-and-home-furnishing-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3253556-amazon-shadow-hangs-over-furniture-and-home-furnishing-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253555\" data-ts=\"1490622660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253555-u-s-court-annuls-of-samarco-class-action-suit-vale-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. court annuls most of Samarco class action suit, Vale says</a></h4><ul>     <li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-5.3%</font>) says a U.S. district court has <a href=\"http://www.reuters.com/article/brazil-vale-lawsuit-idUSL2N1H1285\" target=\"_blank\">annulled nearly all parts</a> of a class action lawsuit against the company and executives over the 2015 Samarco tailings dam collapse that killed 19 people in Brazil.</li>     <li>Vale says the only parts of the case that remain ongoing are linked to specific statements the company made in 2013-14 and a conference call in November 2015.</li><li>Vale jointly runs the Samarco mine with BHP Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-3.3%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253555\" data-linked=\"U.S. court annuls most of Samarco class action suit, Vale says\" data-tweet=\"$VALE $VALE $BHP - U.S. court annuls most of Samarco class action suit, Vale says https://seekingalpha.com/news/3253555-u-s-court-annuls-of-samarco-class-action-suit-vale-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3253555-u-s-court-annuls-of-samarco-class-action-suit-vale-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253545\" data-ts=\"1490621203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSAT\" target=\"_blank\">NSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253545-norsat-to-be-acquired-hytera-communications\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Norsat to be acquired by Hytera Communications</a></h4><ul>   <li>Norsat (NYSEMKT:<a href='https://seekingalpha.com/symbol/NSAT' title='Norsat International Inc.'>NSAT</a>) came off a halt <font color='green'>up 4.7%</font> premarket (to $10.05) after entering a <a href=\"https://seekingalpha.com/pr/16781189-norsat-enters-definitive-agreement-hytera-communications-co-ltd-acquired-10_25-usd-per-share\" target=\"_blank\">definitive deal</a> to be acquired by Hytera Communications for $10.25/share.</li>    <li>The deal has a termination fee of $2M, and provides for nonsolicitation provisions along with \"fiduciary out\" provisions.</li>    <li>The buyout has unanimous support of Norsat's independent directors. It will come to a vote at an upcoming special meeting, requiring two-thirds support to go through.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253545\" data-linked=\"Norsat to be acquired by Hytera Communications\" data-tweet=\"$NSAT - Norsat to be acquired by Hytera Communications https://seekingalpha.com/news/3253545-norsat-to-be-acquired-hytera-communications?source=tweet\" data-url=\"https://seekingalpha.com/news/3253545-norsat-to-be-acquired-hytera-communications\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253539\" data-ts=\"1490620902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253539-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/FOMX' title='Foamix Pharmaceuticals'>FOMX</a>&nbsp;<font color='red'>-50%</font>&nbsp;on&nbsp;mixed results from two Phase 3 clinical trials.</li><li><a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-14%&nbsp;</font>on Q4 earnings miss.</li><li><a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='red'>-5%</font>&nbsp;on infrastructure spending worries by Trump administration.</li><li><a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253539\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$FOMX $GIII $CLF - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3253539-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3253539-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253543\" data-ts=\"1490620839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UN\" target=\"_blank\">UN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253543-pressure-mounts-on-unilever-after-kraft-snub\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pressure mounts on Unilever after Kraft snub</a></h4><ul> <li>A new sense of urgency is in place at Unilever (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a>, <a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a>) after the company rejected a $143B buyout offer from Kraft Heinz, says Liberum.</li> <li>The firm thinks Unilever is likely to shed some assets and return cash to shareholders after completing its strategic review in April.</li> <li>\"Consensus factors in more aggressive margin uplift over the next three years and speculation is rife about disposals and/or large shareholder returns,\" Liberum tells clients.</li> <li>Liberum rates Unilever at Hold after having it set at Sell previously.</li> <li>Last Friday, Barclays <a href=\"http://www.proactiveinvestors.co.uk/companies/news/175448/krafts-aborted-bid-for-unilever-has-piqued-interest-in-the-stock-175448.html\" target=\"_blank\">upgraded</a> the consumer products stock to Overweight. \"Unilever was arguably on the right course to improving profitability - but there's nothing like a little external pressure to expedite the process (whilst also forcing its hand into other means of value creation),\" reads the Barclays note.</li> <li>UN <font color='green'>+1.03%</font> premarket. UL <font color='green'>+0.84%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253543\" data-linked=\"Pressure mounts on Unilever after Kraft snub\" data-tweet=\"$UN $UN $UL - Pressure mounts on Unilever after Kraft snub https://seekingalpha.com/news/3253543-pressure-mounts-on-unilever-after-kraft-snub?source=tweet\" data-url=\"https://seekingalpha.com/news/3253543-pressure-mounts-on-unilever-after-kraft-snub\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253542\" data-ts=\"1490620735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253542-new-chief-impax-labs-shares-up-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief at Impax Labs; shares up 12% premarket</a></h4><ul><li>Impax Laboratories (IPXL) <a href=\"http://investors.impaxlabs.com/Media-Center/Press-Releases/Press-Release-Details/2017/Impax-Board-of-Directors-Appoints-Paul-M-Bisaro-President-and-CEO/default.aspx\" target=\"_blank\">appoints </a>Paul Bisaro as President &amp; CEO effective today, succeeding interim chief Kevin Buchi.</li><li>Mr. Bisaro was formerly Executive Chairman of Allergan and President &amp; CEO of Actavis.</li><li>Shares are up&nbsp;<font color='green'>12%</font>&nbsp;premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253542\" data-linked=\"New chief at Impax Labs; shares up 12% premarket\" data-tweet=\"$AMRX - New chief at Impax Labs; shares up 12% premarket https://seekingalpha.com/news/3253542-new-chief-impax-labs-shares-up-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253542-new-chief-impax-labs-shares-up-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253541\" data-ts=\"1490620711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AU\" target=\"_blank\">AU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253541-gold-futures-rise-to-highest-level-in-month\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold futures rise to highest level in a month</a></h4><ul>     <li>While base metals tumble, precious metals are <a href=\"http://www.marketwatch.com/story/gold-rises-to-highest-level-in-a-month-after-gop-health-bill-flops-2017-03-27\" target=\"_blank\">moving higher</a>, benefiting from safe haven demand after Friday's failure to pass health care reform in the U.S. Congress.</li>     <li>April gold gains ~$10, <font color='green'>+0.8%</font>, to $1,258.50/oz., and silver adds ~0.20, or <font color='green'>+1.1%</font>, to $17.95/oz.</li>     <li>Among premarket movers: <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+3.9%,</font> <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='green'>+3.3%</font>, <a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='green'>+2.6%</font>, SLW <font color='green'>+2.6%</font>, ABX <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a> <font color='green'>+2.3%</font>, <a href='https://seekingalpha.com/symbol/AEM' title='Agnico Eagle Mines Limited'>AEM</a> <font color='green'>+2.3%</font>.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a>, <a href='https://seekingalpha.com/symbol/AGQ' title='ProShares Ultra Silver ETF'>AGQ</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/SIL' title='Global X Silver Miners ETF'>SIL</a>, <a href='https://seekingalpha.com/symbol/JNUG' title='Direxion Daily Junior Gold Miners Index Bull 3x Shares ETF'>JNUG</a>, <a href='https://seekingalpha.com/symbol/USLV' title='VelocityShares 3x Long Silver ETN'>USLV</a>, <a href='https://seekingalpha.com/symbol/ZSL' title='ProShares UltraShort Silver ETF'>ZSL</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/JDST' title='Direxion Daily Junior Gold Miners Index Bear 3x Shares ETF'>JDST</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/DSLV' title='VelocityShares 3x Inverse Silver ETN'>DSLV</a>, <a href='https://seekingalpha.com/symbol/SLVP' title='iShares MSCI Global Silver Miners ETF'>SLVP</a>, <a href='https://seekingalpha.com/symbol/DGL' title='Inv DB Mul-Sec Shs Invesco DB Gold Fund'>DGL</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/DBS' title='Invesco DB Silver ETF'>DBS</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/PSAU' title='Invesco Global Gold and Precious Metals Portfolio ETF'>PSAU</a>, <a href='https://seekingalpha.com/symbol/SGDJ' title='Sprott Junior Gold Miners ETF'>SGDJ</a>, <a href='https://seekingalpha.com/symbol/TGLDX' title='Tocqueville Gold Fund No Load'>TGLDX</a>, <a href='https://seekingalpha.com/symbol/USV' title='UBS ETRACS CMCI Silver Total Return ETN'>USV</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/GDJJ' title='ProShares Ultra Junior Miners ETF'>GDJJ</a>, <a href='https://seekingalpha.com/symbol/GDXX' title='ProShares Ultra Gold Miners ETF'>GDXX</a>, <a href='https://seekingalpha.com/symbol/GDXS' title='ProShares UltraShort Gold Miners ETF'>GDXS</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3253541\" data-linked=\"Gold futures rise to highest level in a month\" data-tweet=\"$AU $AU $AG - Gold futures rise to highest level in a month https://seekingalpha.com/news/3253541-gold-futures-rise-to-highest-level-in-month?source=tweet\" data-url=\"https://seekingalpha.com/news/3253541-gold-futures-rise-to-highest-level-in-month\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253540\" data-ts=\"1490620649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253540-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+27%</font> continues winning streak from Friday.<br></li><li><a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='green'>+23%</font> after successful completion of first stem cell transplant procedure using the company's ApoGraft technology.</li><li><a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+17%</font>.</li><li><a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='green'>+15%</font> on thin volume after Allergan's sarecycline studies met their 12-week primary endpoint.</li><li>IPXL <font color='green'>+11%</font> on appointment of Paul M. Bisaro as President and CEO.<br></li><li><a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a> <font color='green'>+9%</font> on forming OneStim joint venture with Schlumberger.</li><li><a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253540\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$HTGM $APOP $GBR - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3253540-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3253540-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253537\" data-ts=\"1490620221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APOP\" target=\"_blank\">APOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253537-first-clinical-trial-patient-treated-cellect-bios-apograft-shares-ahead-22-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First clinical trial patient treated with Cellect Bio&#39;s ApoGraft; shares ahead 22% premarket</a></h4><ul><li>Cellect Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a>) heads north&nbsp;<font color='green'>22%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16781096-cellect-announces-successful-first-cancer-patient-stem-cell-transplant\" target=\"_blank\">announcement </a>that the first cell transplant procedure has been performed using its ApoGraft technology in a blood cancer patient in its <a href=\"https://clinicaltrials.gov/ct2/show/NCT02828878?term=NCT02828878&amp;rank=1\" target=\"_blank\">Phase 1/2 clinical trial</a>.</li><li>According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint safety is February 2018. The estimated study completion date is September 2018.</li><li>ApoGraft is a stem cell selection process designed to reduce the risk of rejection known as Graft-versus-Host Disease (GvHD). The condition, occurring in as many as 50% of stem cell transplants, can be life-threatening.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253537\" data-linked=\"First clinical trial patient treated with Cellect Bio&#39;s ApoGraft; shares ahead 22% premarket\" data-tweet=\"$APOP - First clinical trial patient treated with Cellect Bio&#39;s ApoGraft; shares ahead 22% premarket https://seekingalpha.com/news/3253537-first-clinical-trial-patient-treated-cellect-bios-apograft-shares-ahead-22-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253537-first-clinical-trial-patient-treated-cellect-bios-apograft-shares-ahead-22-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253536\" data-ts=\"1490620077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MS\" target=\"_blank\">MS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253536-morgan-stanleyminus-2_5-after-downgrade-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley -2.5% after downgrade to Sell</a></h4><ul><li>A Sell rating on a major bank is a rare bird these days, but leave it to lonely bear Charles Peabody (now at Compass Point).</li><li>He cuts Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>) to Sell from Neutral, with price target of $34 (down from $46) suggesting about&nbsp;<font color='red'>20% downside</font>.</li><li>Shares&nbsp;<font color='red'>-2.5%</font>&nbsp;to $41.40 premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253536\" data-linked=\"Morgan Stanley -2.5% after downgrade to Sell\" data-tweet=\"$MS - Morgan Stanley -2.5% after downgrade to Sell https://seekingalpha.com/news/3253536-morgan-stanleyminus-2_5-after-downgrade-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3253536-morgan-stanleyminus-2_5-after-downgrade-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253531\" data-ts=\"1490619408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABCO\" target=\"_blank\">ABCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253531-advisory-board-company-perks-up-after-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Advisory Board Company perks up after upgrade</a></h4><ul> <li>Baird <a href=\"https://twitter.com/usratings/status/846316729684910080\" target=\"_blank\">upgrades</a> The Advisory Board Company (NASDAQ:<a href='https://seekingalpha.com/symbol/ABCO' title='The Advisory Board Company'>ABCO</a>) to an Outperform rating after having it set at Neutral.</li> <li>The firm ups its price target to $53, a level not seen for the stock in about 18 months.</li> <li>ABCO <font color='green'>+1.24%</font> premarket to $45.25.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253531\" data-linked=\"The Advisory Board Company perks up after upgrade\" data-tweet=\"$ABCO - The Advisory Board Company perks up after upgrade https://seekingalpha.com/news/3253531-advisory-board-company-perks-up-after-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3253531-advisory-board-company-perks-up-after-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253530\" data-ts=\"1490619332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253530-ziopharm-poised-to-advance-lead-gene-therapy-candidate-phase-3-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZIOPHARM poised to advance lead gene therapy candidate into Phase 3; shares ahead 5% premarket</a></h4><ul><li>ZIOPHARM Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) perks up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16781238-ziopharm-announces-successful-end-phase-2-meeting-fda-ad-rts-hilminus-12-gene-therapy\" target=\"_blank\">announcement</a> that it has received FDA guidance from an End-of-Phase 2 meeting regarding lead gene therapy candidate Ad-RTS-hIL-12, in combination with orally administered veledimex, for the treatment of an aggressive type of brain cancer called recurrent glioblastoma &#40;GBM&#41;.</li><li>The company plans to advance the gene therapy, which utilizes its RheoSwitch platform, into Phase 3 development this year. It will release details about the protocol design after completed discussions with clinical advisors and regulators.</li><li>Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of&nbsp;<a href=\"http://en.wikipedia.org/wiki/Interleukin_12\" target=\"_blank\">interleukin-12</a>&nbsp;(IL-12), an essential protein for stimulating a T cell immune response to cancer.&nbsp;<a href=\"http://investors.dna.com/phoenix.zhtml?c=249599&amp;p=irol-newsArticle_Print&amp;ID=1994675\" target=\"_blank\">Veledimex&nbsp;</a>is an oral activator ligand or \"gene switch\" which is used to control the expression of IL-12, a pro-inflammatory cytokine that produces serious side effects if over-expressed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253530\" data-linked=\"ZIOPHARM poised to advance lead gene therapy candidate into Phase 3; shares ahead 5% premarket\" data-tweet=\"$ZIOP - ZIOPHARM poised to advance lead gene therapy candidate into Phase 3; shares ahead 5% premarket https://seekingalpha.com/news/3253530-ziopharm-poised-to-advance-lead-gene-therapy-candidate-phase-3-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253530-ziopharm-poised-to-advance-lead-gene-therapy-candidate-phase-3-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253528\" data-ts=\"1490618929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253528-dryships-acquires-four-modern-newcastlemax-vessels\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dryships acquires four modern Newcastlemax vessels</a></h4><ul> <li>DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>)&nbsp;announced hat it has entered into agreements with unaffiliated third parties to acquire four modern Newcastlemax bulk carriers of approximately 206K DWT and with an average age of 3.0 years.</li><li>The company says it expects to take delivery of the vessels before the end of June.</li> <li>The gross purchase price of approximately $124M will be financed using cash on hand.</li><li>DryShips reports current liquidity of ~$455M.</li>  <li>DRYS  <font color='red'>-1.48%</font> premarket to  $1.33.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16781382-dryships-inc-announces-acquisition-four-modern-newcastlemax-vessels\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253528\" data-linked=\"Dryships acquires four modern Newcastlemax vessels\" data-tweet=\"$DRYS - Dryships acquires four modern Newcastlemax vessels https://seekingalpha.com/news/3253528-dryships-acquires-four-modern-newcastlemax-vessels?source=tweet\" data-url=\"https://seekingalpha.com/news/3253528-dryships-acquires-four-modern-newcastlemax-vessels\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253527\" data-ts=\"1490618796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKS\" target=\"_blank\">AKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253527-base-metals-miners-slide-on-infrastructure-spending-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Base metals miners slide on infrastructure spending worries</a></h4><ul>     <li>If Pres. Trump and a Republican congress can't agree on a path to replace Obamacare, what does that mean for Trump's infrastructure spending plans?</li>     <li>That's part of what's driving down shares of industrial metals miners in premarket trade:&nbsp;<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='red'>-5.4%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='red'>-4.9%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='red'>-4.6%</font>, <a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='red'>-3.7%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='red'>-4.6%</font>, <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='red'>-2.2%</font>.</li>     <li>Metals prices also face pressure following curbs on financing in China&rsquo;s housing sector, with <a href=\"https://www.businessinsider.com.au/iron-ore-price-dalian-futures-smoked-2017-3\" target=\"_blank\">iron ore futures sharply lower</a> on the Dalian Commodity Exchange.</li><li>As a result, the top global iron ore producers are lower premarket: <a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-3.9%</font>, <a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-2.7%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-1.5%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLB' title='Materials Select Sector SPDR ETF'>XLB</a>, <a href='https://seekingalpha.com/symbol/XME' title='SPDR S&P Metals and Mining ETF'>XME</a>, <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a>, <a href='https://seekingalpha.com/symbol/PEO' title='Adams Natural Resources Fund, Inc.'>PEO</a>, <a href='https://seekingalpha.com/symbol/VAW' title='Vanguard Materials ETF'>VAW</a>, <a href='https://seekingalpha.com/symbol/DBB' title='Invesco DB Base Metals ETF'>DBB</a>, <a href='https://seekingalpha.com/symbol/UYM' title='ProShares Ultra Basic Materials ETF'>UYM</a>, <a href='https://seekingalpha.com/symbol/IYM' title='iShares U.S. Basic Materials ETF'>IYM</a>, <a href='https://seekingalpha.com/symbol/JJN' title='iPath DJ-UBS Nickel Total Return Sub-Index ETN'>JJN</a>, <a href='https://seekingalpha.com/symbol/SMN' title='ProShares UltraShort Basic Materials ETF'>SMN</a>, <a href='https://seekingalpha.com/symbol/JJU-OLD' title='iPath Dow Jones-UBS Aluminum Total Return Sub-IndexS ETN'>JJU-OLD</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/BOM' title='DB Base Metals Double Short ETN'>BOM</a>, <a href='https://seekingalpha.com/symbol/JJT-OLD' title='iPath Dow Jones-UBS Tin Total Return Sub-Index ETN'>JJT-OLD</a>, <a href='https://seekingalpha.com/symbol/FXZ' title='First Trust Materials AlphaDEX ETF'>FXZ</a>, <a href='https://seekingalpha.com/symbol/BOS' title='DB Base Metals Short ETN'>BOS</a>, <a href='https://seekingalpha.com/symbol/RJZ' title='ELEMENTS Rogers International Commodity Metal ETN'>RJZ</a>, <a href='https://seekingalpha.com/symbol/LD' title='iPath Dow Jones-UBS Lead Total Return Sub-Index ETN'>LD</a>, <a href='https://seekingalpha.com/symbol/NINI' title='iPath Pure Beta Nickel ETN'>NINI</a>, <a href='https://seekingalpha.com/symbol/RTM' title='Invesco S&P Equal Weight Materials ETF'>RTM</a>, <a href='https://seekingalpha.com/symbol/BDD' title='DB Base Metals Double Long ETN'>BDD</a>, <a href='https://seekingalpha.com/symbol/PYZ' title='Invesco DWA Basic Materials Momentum Portfolio ETF'>PYZ</a>, <a href='https://seekingalpha.com/symbol/FOIL' title='iPath Pure Beta Aluminum ETN'>FOIL</a>, <a href='https://seekingalpha.com/symbol/JJM' title='iPath DJ-UBS Industrial Metals Total Return Sub-Index ETN'>JJM</a>, <a href='https://seekingalpha.com/symbol/CUPM' title='iPath Pure Beta Copper ETN'>CUPM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253527\" data-linked=\"Base metals miners slide on infrastructure spending worries\" data-tweet=\"$AKS $AKS $CLF - Base metals miners slide on infrastructure spending worries https://seekingalpha.com/news/3253527-base-metals-miners-slide-on-infrastructure-spending-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3253527-base-metals-miners-slide-on-infrastructure-spending-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253525\" data-ts=\"1490618570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOMX\" target=\"_blank\">FOMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253525-foamix-pharmas-fmx101-shows-mixed-results-in-two-late-stage-acne-studies-shares-plummet-47\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foamix Pharma&#39;s FMX101 shows mixed results in two late-stage acne studies; shares plummet 47% premarket</a></h4><ul><li>Thinly traded micro cap Foamix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/FOMX' title='Foamix Pharmaceuticals'>FOMX</a>) craters&nbsp;<font color='red'>47%&nbsp;</font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16781114-foamix-reports-topline-results-phase-3-trials-fmx101-patients-acne\" target=\"_blank\">announcement </a>of mixed results from two Phase 3 clinical trials assessing FMX101 in people with moderate-to-severe acne.</li><li>One study, Trial 05, met both co-primary endpoints but the other, Trial 04 only met one. Specifically, both studies showed treatment with FMX101 produced statistically significant reductions in the number of inflammatory lesions versus baseline compared to vehicle (placebo) but only Trial 05 met the other primary endpoint of a statistically significantly greater proportion of patients achieving success as measured by a scale called IGA (14.67% vs 7.89%; p=0.0423). Trial 04 came up short (8.09% vs. 4.77%; p=0.2178).</li><li>The company has yet to complete the full data analysis.</li><li>FMX101 is a proprietary 4% minocycline (antibiotic) foam formulation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253525\" data-linked=\"Foamix Pharma&#39;s FMX101 shows mixed results in two late-stage acne studies; shares plummet 47% premarket\" data-tweet=\"$FOMX - Foamix Pharma&#39;s FMX101 shows mixed results in two late-stage acne studies; shares plummet 47% premarket https://seekingalpha.com/news/3253525-foamix-pharmas-fmx101-shows-mixed-results-in-two-late-stage-acne-studies-shares-plummet-47?source=tweet\" data-url=\"https://seekingalpha.com/news/3253525-foamix-pharmas-fmx101-shows-mixed-results-in-two-late-stage-acne-studies-shares-plummet-47\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253522\" data-ts=\"1490617561\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MIK\" target=\"_blank\">MIK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253522-s-and-p-index-changes-for-mik-and-wetf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">S&amp;P index changes for MIK and WETF</a></h4><ul> <li>Michaels (NASDAQ:<a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies'>MIK</a>) trades higher after getting the call-up to join the S&amp;P MidCap 400.</li> <li>The retailer replaces WisdomTree Investments (NASDAQ:<a href='https://seekingalpha.com/symbol/WETF' title='WisdomTree Investments, Inc.'>WETF</a>) which is moving to the S&amp;P SmallCap 600.</li> <li><a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/503555_wisdomendurmikeshoe46.pdf?force_download=true\" target=\"_blank\">S&amp;P press release</a></li> <li>MIK <font color='green'>+2.91%</font> premarket to $22.60. WETF <font color='red'>-1.61%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253522\" data-linked=\"S&amp;P index changes for MIK and WETF\" data-tweet=\"$MIK $MIK $WETF - S&amp;P index changes for MIK and WETF https://seekingalpha.com/news/3253522-s-and-p-index-changes-for-mik-and-wetf?source=tweet\" data-url=\"https://seekingalpha.com/news/3253522-s-and-p-index-changes-for-mik-and-wetf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253521\" data-ts=\"1490617394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253521-btig-raises-adobe-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BTIG raises Adobe to Buy</a></h4><ul><li>Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) has been <a href=\"https://www.streetinsider.com/Analyst+Comments/BTIG+Upgrades+Adobe+to+Buy/12707340.html\" target=\"_blank\">upgraded</a> to Buy from Neutral at BTIG, which projects sustained growth in cash flow and earnings over the next few years.</li><li>The firm also assigned the software maker's stock a price target of $151.</li><li>ADBE <font color='green'>+1.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3253521\" data-linked=\"BTIG raises Adobe to Buy\" data-tweet=\"$ADBE - BTIG raises Adobe to Buy https://seekingalpha.com/news/3253521-btig-raises-adobe-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3253521-btig-raises-adobe-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253516\" data-ts=\"1490617118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253516-g-iii-apparel-down-after-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G-III Apparel down after Q4 results</a></h4><ul>     <li>G-III Apparel (NASDAQ:<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a>) reports net sales rose 14.4% in <a href=\"https://seekingalpha.com/pr/16781061-g-iii-apparel-group-ltd-announces-fourth-quarter-full-year-fiscal-2017-results\" target=\"_blank\">Q4</a>, due to strength in the non-outerwear wholesale business, including new product launches, as well as the inclusion of ~$29M of net sales from the DKI business in the last two months of the quarter.</li>     <li>Gross margin rate squeezed 110 bps to 32.8%.</li>     <li>SG&amp;A expense rate expanded 290 bps to 33.1%.</li>     <li>Inventory -0.4% to $483.27M.</li>     <li><b>Q1 Guidance</b>: Net sales: ~$500M; Net loss: $20M to $25M; Diluted EPS: -$0.41 to -$0.51; Adjusted EPS: -$0.35 to -$0.45.</li>     <li><b>FY2018 Guidance</b>:&nbsp;Net sales: ~$2.73B; D&amp;A: $39M;&nbsp;Interest and financing charges, net: $51M; Income tax expense: $23M to $27M;&nbsp;Net income: $40M to $45M; Diluted EPS: $0.80 to $0.90; Adjusted EPS: $0.99 to $1.09; Adjusted EBITDA: $162M to $171M.</li>     <li>GIII&nbsp;<font color='red'>-12.78%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253516\" data-linked=\"G-III Apparel down after Q4 results\" data-tweet=\"$GIII - G-III Apparel down after Q4 results https://seekingalpha.com/news/3253516-g-iii-apparel-down-after-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3253516-g-iii-apparel-down-after-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253515\" data-ts=\"1490616968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253515-appleminus-0_85-pre-susquehanna-cautious-on-iphone-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple -0.85% pre; Susquehanna cautious on iPhone 8</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls</a></li><li>Meetings in Taiwan and Korea last week suggest build plans for the iPhone 8 have recently been revised lower, says Susquehanna, which now thinks Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) is planning to build and ship only about 100M units in H2 vs. a previous expectation for 110M-115M.</li><li>FBN's Shelby Sherafy is cautious as well given the stock's recent one-way trip higher. He's not downgrading, but expects the iPhone 8 will just a good cycle, not a \"supercycle.\"</li><li>Shares<font color='red'> -0.85%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3253515\" data-linked=\"Apple -0.85% pre; Susquehanna cautious on iPhone 8\" data-tweet=\"$AAPL - Apple -0.85% pre; Susquehanna cautious on iPhone 8 https://seekingalpha.com/news/3253515-appleminus-0_85-pre-susquehanna-cautious-on-iphone-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3253515-appleminus-0_85-pre-susquehanna-cautious-on-iphone-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253513\" data-ts=\"1490616920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDC\" target=\"_blank\">DDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253513-dominion-diamond-to-explore-strategic-alternativesplus-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dominion Diamond to explore strategic alternatives; +4% premarket</a></h4><ul>     <li>Dominion Diamond (NYSE:<a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a>)&nbsp;<font color='green'>+4.1%</font> premarket after saying it will <a href=\"https://seekingalpha.com/pr/16780991-dominion-diamond-announces-exploration-strategic-alternatives\" target=\"_blank\">explore strategic alternatives</a>, including a possible sale of the company.</li>     <li>The announcement comes just a week after Washington Cos., a group of North American mining, railroad and transportation assets, went public with a $13.50/share <a href=\"https://seekingalpha.com/news/3252120-washington-cos-makes-move-dominion-diamond\" target=\"_blank\">unsolicited takeover offer</a> for DDC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253513\" data-linked=\"Dominion Diamond to explore strategic alternatives; +4% premarket\" data-tweet=\"$DDC - Dominion Diamond to explore strategic alternatives; +4% premarket https://seekingalpha.com/news/3253513-dominion-diamond-to-explore-strategic-alternativesplus-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253513-dominion-diamond-to-explore-strategic-alternativesplus-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253510\" data-ts=\"1490616436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARQL\" target=\"_blank\">ARQL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253510-arqules-lead-product-candidate-tivantinib-flunks-late-state-liver-cancer-study-in-japan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArQule&#39;s lead product candidate tivantinib flunks late-state liver cancer study in Japan; shares plummet 22% premarket</a></h4><ul><li>Thinly traded nano cap ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) comes up empty again with lead product candidate tivantinib. A Phase 3 clinical trial, JET-HCC, in 190 Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma &#40;HCC&#41; previously treated with sorafenib (Bayer's <a href=\"https://www.nexavar-us.com/\" target=\"_blank\">Nexavar</a>) <a href=\"https://seekingalpha.com/pr/16781051-arqule-announces-top-line-results-phase-3-clinical-study-tivantinib-hepatocellular-carcinoma\" target=\"_blank\">failed to beat placebo</a> as measured by progression-free survival &#40;PFS&#41;.</li><li>Detailed results will be presented at an upcoming scientific meeting.</li><li>In February, tivantinib failed to beat best supportive care in a late-stage HCC study.</li><li>Shares are down&nbsp;<font color='red'>22%</font>&nbsp;premarket on average volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3244454-arqules-lead-product-candidate-tivantinib-flunks-late-stage-liver-cancer-study-shares-16\" target=\"_blank\">ArQule's lead product candidate tivantinib flunks late-stage liver cancer study; shares down 16%</a> (Feb. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253510\" data-linked=\"ArQule&#39;s lead product candidate tivantinib flunks late-state liver cancer study in Japan; shares plummet 22% premarket\" data-tweet=\"$ARQL - ArQule&#39;s lead product candidate tivantinib flunks late-state liver cancer study in Japan; shares plummet 22% premarket https://seekingalpha.com/news/3253510-arqules-lead-product-candidate-tivantinib-flunks-late-state-liver-cancer-study-in-japan?source=tweet\" data-url=\"https://seekingalpha.com/news/3253510-arqules-lead-product-candidate-tivantinib-flunks-late-state-liver-cancer-study-in-japan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253501\" data-ts=\"1490615833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253501-modest-equity-selloff-sends-bond-yields-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Modest equity selloff sends bond yields lower</a></h4><ul><li>Asia was lit up red overnight, as is Europe at midday. Leading to the downside was the Nikkei<font color='red'> -1.4%</font>&nbsp;and Germany&nbsp;<font color='red'>-0.75%</font>. U.S. stock index futures are all&nbsp;<font color='red'>down in the area of 0.75%</font>.</li><li>The failure of health reform and what it might mean for Trump tax and regulatory reform agenda is makes for a nice excuse for headline writers, but stocks (at least in the U.S.) haven't had even the most modest of setbacks since the election. The S&amp;P 500 is down only about 3% since March 1.</li><li>The 10-year Treasury yield has returned to the near the bottom of the 2.30-2.60% channel it's been in since shortly after the election. It's down 5.8 basis points this morning to 2.36%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.7%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-1.4%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253501\" data-linked=\"Modest equity selloff sends bond yields lower\" data-tweet=\"$TLT $TBT $TMV - Modest equity selloff sends bond yields lower https://seekingalpha.com/news/3253501-modest-equity-selloff-sends-bond-yields-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3253501-modest-equity-selloff-sends-bond-yields-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253500\" data-ts=\"1490615744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253500-allergans-oral-antibiotic-successful-in-two-late-stage-acne-studies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan&#39;s oral antibiotic successful in two late-stage acne studies</a></h4><ul><li>Two Phase 3 clinical trials assessing Allergan's (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) orally administered sarecycline in people with moderate-to-severe acne <a href=\"https://seekingalpha.com/pr/16781130-allergan-paratek-announce-positive-results-two-phase-3-trials-sarecycline-treatment-moderate\" target=\"_blank\">met their 12-week primary efficacy endpoints</a>. Based on the successful results, it intends to file a New Drug Application &#40;NDA&#41; with the FDA in H2.</li><li>Participants receiving 1.5 mg/kg/day of sarecycline experienced statistically significant reductions in inflammatory lesion counts compared to placebo.</li><li>The most common adverse events in the treatment group were nausea (3.2%), nasopharyngitis (2.8%) and headache (2.8%). The discontinuation rate in the combined studies was 1.4%.</li><li>Allergan obtained the U.S. rights to sarecycline, a narrow spectrum tetracycline-derived antibiotic, from from Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>).</li><li>Paratek is up&nbsp;<font color='green'>11%</font>&nbsp;premarket but only on 320 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253500\" data-linked=\"Allergan&#39;s oral antibiotic successful in two late-stage acne studies\" data-tweet=\"$AGN $AGN $PRTK - Allergan&#39;s oral antibiotic successful in two late-stage acne studies https://seekingalpha.com/news/3253500-allergans-oral-antibiotic-successful-in-two-late-stage-acne-studies?source=tweet\" data-url=\"https://seekingalpha.com/news/3253500-allergans-oral-antibiotic-successful-in-two-late-stage-acne-studies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253496\" data-ts=\"1490614771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUPH\" target=\"_blank\">AUPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253496-aurinia-pharmas-voclosporin-shows-sustained-treatment-benefit-in-ln-patients-after-48-weeks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurinia Pharma&#39;s voclosporin shows sustained treatment benefit in LN patients after 48 weeks; shares ahead 6% premarket</a></h4><ul><li>Aurinia Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a>) perks up&nbsp;<font color='green'>6%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/filing/3474910\" target=\"_blank\">announcement </a>of positive results from an open-label study, AURION, assessing lead product candidate voclosporin in patients with lupus nephritis &#40;LN&#41;. The results were presented at the 12th International Congress on Systemic Lupus Erythematosus and 7th Asian Congress on Autoimmunity in Melbourne, Australia.</li><li>The study met its primary endpoint of demonstrating that early biomarker response in active LN patients can be a significant predictor of renal response at weeks 24 and 48.</li><li>At week 48, 71% (n=5/7) of subjects on treatment remained in complete remission as measured by urinary protein creatinine ratio &#40;UPCR&#41; of no more than -0.5 mg/mg and other metrics. A 25% reduction in UPCR at week 8 was found to be highly predictive of achieving renal response at weeks 24 and 48.</li><li>AURION is a 10-subject exploratory study being conducted in Malaysia.</li><li><a href=\"http://www.auriniapharma.com/dnn/ProductsInDevelopment/Voclosporin/WhatisVoclosporin.aspx\" target=\"_blank\">Voclosporin&nbsp;</a>suppresses the immune system by&nbsp;inhibiting an enzyme called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Calcineurin\" target=\"_blank\">calcineurin</a>, which activates T cells. Its value proposition&nbsp;is&nbsp;similar effectiveness to other calcineurin&nbsp;inhibitors (cyclosporin and tacrolimus) without the deleterious side effects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253496\" data-linked=\"Aurinia Pharma&#39;s voclosporin shows sustained treatment benefit in LN patients after 48 weeks; shares ahead 6% premarket\" data-tweet=\"$AUPH - Aurinia Pharma&#39;s voclosporin shows sustained treatment benefit in LN patients after 48 weeks; shares ahead 6% premarket https://seekingalpha.com/news/3253496-aurinia-pharmas-voclosporin-shows-sustained-treatment-benefit-in-ln-patients-after-48-weeks?source=tweet\" data-url=\"https://seekingalpha.com/news/3253496-aurinia-pharmas-voclosporin-shows-sustained-treatment-benefit-in-ln-patients-after-48-weeks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253474\" data-ts=\"1490611964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MESO\" target=\"_blank\">MESO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253474-mesoblast-completes-40m-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mesoblast completes $40M capital raise</a></h4><ul><li>Mesoblast (NASDAQ:<a href='https://seekingalpha.com/symbol/MESO' title='Mesoblast'>MESO</a>) <a href=\"https://seekingalpha.com/pr/16780998-mesoblast-raises-us-40-million\" target=\"_blank\">finalizes </a>the institutional placement of 26.25M newly issued shares at A$2.00, an almost 5% discount to the 15-day volume-weighted average price &#40;VWAP&#41; of A$2.10.</li><li>Proceeds of US$40M will fund the company's ongoing Phase 3 clinical programs and manufacturing requirements to support product commercialization.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253474\" data-linked=\"Mesoblast completes $40M capital raise\" data-tweet=\"$MESO - Mesoblast completes $40M capital raise https://seekingalpha.com/news/3253474-mesoblast-completes-40m-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3253474-mesoblast-completes-40m-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253472\" data-ts=\"1490611795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALM\" target=\"_blank\">CALM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253472-cal-maine-foods-lower-post-fq3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cal-Maine Foods lower post FQ3 results</a></h4><ul>     <li>Cal-Maine Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/CALM' title='Cal-Maine Foods, Inc.'>CALM</a>)&nbsp;reports egg sales declined 5% Y/Y to 263.613M in FQ3.</li>     <li>Specialty-egg sales accounted for 40.8% of total revenue, up 980 bps Y/Y.</li>     <li>Average price -27.9% to $1.130 per dozen.</li>     <li>Gross margin rate fell 1670 bps to 12.8%.</li>     <li>CALM&nbsp;<font color='red'>-3.61%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253472\" data-linked=\"Cal-Maine Foods lower post FQ3 results\" data-tweet=\"$CALM - Cal-Maine Foods lower post FQ3 results https://seekingalpha.com/news/3253472-cal-maine-foods-lower-post-fq3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3253472-cal-maine-foods-lower-post-fq3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":71,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}